LPS promotes resistance to TRAIL-induced apoptosis in pancreatic cancer
Though TRAIL has been hailed as a promising drug for tumour treatment, it has been observed that many tumour cells have developed escape mechanisms against TRAIL-induced apoptosis. As a receptor of LPS, TLR 4, which is expressed on a variety of cancer cells, can be associated with TRAIL-resistance o...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2017
|
| In: |
Infectious agents and cancer
Year: 2017, Volume: 12 |
| ISSN: | 1750-9378 |
| DOI: | 10.1186/s13027-017-0139-4 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s13027-017-0139-4 Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13027-017-0139-4 
|
| Author Notes: | Katharina Beyer, Lars Ivo Partecke, Felicitas Roetz, Herbert Fluhr, Frank Ulrich Weiss, Claus-Dieter Heidecke and Wolfram von Bernstorff |
| Summary: | Though TRAIL has been hailed as a promising drug for tumour treatment, it has been observed that many tumour cells have developed escape mechanisms against TRAIL-induced apoptosis. As a receptor of LPS, TLR 4, which is expressed on a variety of cancer cells, can be associated with TRAIL-resistance of tumour cells and tumour progression as well as with the generation of an anti-tumour immune response. |
|---|---|
| Item Description: | Published: 30 May 2017 Gesehen am 14.06.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1750-9378 |
| DOI: | 10.1186/s13027-017-0139-4 |